Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its quarterly earnings results on Tuesday, May, 9th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.13. The company had revenue of $110.30 million for the quarter, compared to the consensus estimate of $86.03 million. Ionis Pharmaceuticals had a negative return on equity of 120.60% and a negative net margin of 77.30%. The company's revenue for the quarter was up 199.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.52) EPS. View Ionis Pharmaceuticals' Earnings History.

13 brokers have issued 12-month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $17.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $41.73 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

• 1. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
• 2. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
• 3. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (2/27/2017)
• 4. Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)
• 5. Jefferies Group LLC analysts commented, "Pipeline update call focuses on volanesorsen, IONIS-GCGR-Rx & IONIS-FXI- Rx; and BIIB-partnered IONIS-DMPK-2.5-Rx discontinued due to inadequate potency in muscle in Ph1/2. Beyond highly anticipated Spinraza launch (our 2021E sales of $1.6B vs. BIIB cons of $1.4B, implying royalties to IONS of ~$250M), we view current pipeline products unlikely to drive further meaningful appreciation in IONS shares from its already hefty valuation (EV of ~$5.5B)." (1/6/2017)

Ionis Pharmaceuticals saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 13,332,120 shares, an increase of 15.9% from the April 13th total of 11,507,042 shares. Based on an average daily volume of 1,428,282 shares, the days-to-cover ratio is currently 9.3 days. Currently, 10.9% of the company's stock are sold short.

Some companies that are related to Ionis Pharmaceuticals include Dr.Reddy's Laboratories Ltd (RDY), United Therapeutics (UTHR), Endo International plc - (ENDP), Synergy Pharmaceuticals (SGYP), Amarin Co. plc (AMRN), Amphastar Pharmaceuticals (AMPH), Depomed (DEPO), Sucampo Pharmaceuticals (SCMP), SciClone Pharmaceuticals (SCLN), DURECT (DRRX), Summit Therapeutics PLC (SMMT), Merus Labs International (MSLI), Cardiome Pharma Corp (CRME), Albireo Pharma (ALBO), Cumberland Pharmaceuticals (CPIX), Aralez Pharmaceuticals (ARLZ), MEI Pharma (MEIP) and Orexigen Therapeutics (OREX).

Ionis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (7.63%), Wellington Management Group LLP (7.56%), Baillie Gifford & Co. (6.32%), BB Biotech AG (6.03%) and BlackRock Inc. (5.30%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY, Baillie Gifford & Co., Waddell & Reed Financial Inc., Scout Investments Inc., First Trust Advisors LP, Renaissance Technologies LLC, Pinnacle Associates Ltd. and Tocqueville Asset Management L.P.. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Ionis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wellington Management Group LLP, State Street Corp, BB Biotech AG, Vanguard Group Inc., FMR LLC, Gotham Asset Management LLC and Credit Suisse AG. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $46.35.